ArticleJMIR research protocols2026

Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a, Double-Blinded Randomized Controlled Trial.

George Peter Judicate et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.